RxDoctor Payments Data

Corrine Garner, DO

Family Medicine · Mason, MINPI 1275540825

Payments from drug & device makers

$1,635in general payments, 2019–2025

Across 72 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$698
  • AstraZeneca$246
  • Lilly USA, LLC$177
  • Takeda Pharmaceuticals U.S.A., Inc.$117
  • Pfizer$84
  • AbbVie$79
  • plus $233 from 9 others

What the payments were for

  • Food & beverage$1,62099%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,635 in reported general payments places this provider in the 75th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$17,346
Medicare patients
49
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$22,233
OzempicSemaglutide11$19,102
FarxigaDapagliflozin Propanediol11$18,195
ArexvyRsvpref3 Antigen/As01e/Pf47$14,259
JardianceEmpagliflozin16$13,355
TrulicityDulaglutide12$11,029
Trijardy XrEmpaglifloz/Linaglip/Metformin11$10,948
Tresiba Flextouch U-200Insulin Degludec11$7,512
ShingrixVaricella-Zoster Ge/As01b/Pf26$5,491
Arnuity ElliptaFluticasone Furoate12$2,523
Estradiol15$2,438
Levothyroxine Sodium175$2,135
Atorvastatin Calcium129$1,534
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen84$1,475
Duloxetine Hcl26$1,441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arexvy, Shingrix, Arnuity Ellipta$48$44,506104 claims
Boehringer IngelheimJardiance, Trijardy Xr$15$24,30327 claims
Novo NordiskOzempic$698$19,10211 claims
AstraZenecaFarxiga$246$18,19511 claims
Lilly USA, LLCTrulicity$177$11,02912 claims
AbbVieArmour Thyroid$79$1,14711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Mason

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →